Active Ingredients:Oxybutynin (Ox-y-BEWT-ee-nin)
What is in this leaflet
This leaflet answers some common questions about the OXYTROL®transdermal drug delivery system (patch). It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist.
All medicines have risks and benefits. Your doctor has weighed the risks of you being given OXYTROL®against the benefits they expect it will have for you.
If you have any concerns about being given this medicine, ask your doctor or pharmacist.
Keep this leaflet.
You may need to read it again.
What it looks like
Each OXYTROL®patch is rectangular shape, slightly opaque, and is 39 cm2. Printed on each patch are the words "OXYTROL® 3.9 mg/day".
The patch is composed of three layers. Layer 1 is a backing film which protects the adhesive/drug layer. Layer 2 is the adhesive/drug layer. Layer 3 is a release liner made up of 2 polyester strips that should be peeled off and discarded prior to applying the patch.
Each box of OXYTROL®contains 8 patches (one month's treatment).
Each OXYTROL®transdermal patch contains 36 mg of oxybutynin as the active ingredient and delivers approximately 3.9 mg of oxybutynin per day.
The other ingredients are:
- glycerol triacetate,
- acrylic adhesive solution (containing 2-ethylhexyl acrylate, N-vinyl pyrrolidone and hexamethyleneglycol dimethacrylate polymer domains),
- clear backing film of polyester /ethylene vinyl acetate (PET/EVA), and
- siliconised polyester release liner (PET).
This medicine does not contain lactose, sucrose, gluten, tartrazine or any other azo dyes.
Hospira Australia Pty Ltd
ABN 58 097 064 330
Level 3, 390 St Kilda Road
Melbourne VIC 3004
Hospira NZ Limited
23 Haining Street
Te Aro, Wellington
OXYTROL®is a registered trademark of Watson Pharma Inc. used under licence
This leaflet was prepared in January 2008